Ten-eleven translocation (Tet) proteins are key players involved in the dynamic regulation of cytosine methylation and demethylation. Inactivating mutations of Tet2 are frequently found in human malignancies, highlighting the essential role of Tet2 in cellular transformation. However, the factors that control Tet enzymatic activity remain largely unknown. Here, we found that methyl-CpGbinding domain protein 3 (MBD3) and its homolog MBD3-like 2 (MBD3L2) can specifically modulate the enzymatic activity of Tet2 protein, but not Tet1 and Tet3 proteins, in converting 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC). Moreover, MBD3L2 is more effective than MBD3 in promoting Tet2 enzymatic activity through strengthening the binding affinity between Tet2 and the methylated DNA target. Further analysis revealed pronounced decreases in 5mC levels at MBD3L2 and Tet2 cooccupied genomic regions, most of which are promoter elements associated with either cancer-related genes or genes involved in the regulation of cellular metabolic processes. Our data add new insights into the regulation of Tet2 activity by MBD3 and MBD3L2, and into how that affects Tet2-mediated modulation of its target genes in cancer development. Thus, they have important applications in understanding how dysregulation of Tet2 might contribute to human malignancy.
INTRODUCTION
The ten-eleven translocation (Tet) family, including Tet1, Tet2 and Tet3, are Fe(II)-and α-ketoglutarate (α-KG)-dependent dioxygenases that oxidize 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC). 5hmC can be progressively oxidized into 5-formylcytosine (5fC) and 5-carboxycytosine (5caC), followed by efficient base excision mediated by thymine DNA glycosylase (TDG) and base excision repair (BER), culminating in cytosine replacement and DNA demethylation (He et al., 2011; . 5hmC is mainly enriched at promoters, enhancers and other active chromatin regions, and this leads to gene activation (Fu and He, 2012; Perera et al., 2015) , which indicates that 5hmC formation catalyzed by Tet play roles in regulation of gene expression.
Tet1 is highly expressed in embryonic stem cells (ESCs), and Tet3 is expressed relatively high in germ cells and oocytes, whereas Tet2 is most widely expressed in somatic tissues, especially hematopoietic cells (Wu and Zhang, 2011) . Importantly, Tet2 mutations are frequently found in myeloid malignancies, and Tet2 inactivation in hematopoietic progenitor cells blocks myeloid differentiation (Scopim-Ribeiro et al., 2015) . The reduction of Tet2 activity is strongly correlated with the low 5hmC level in leukemia (Solary et al., 2014) . In addition, loss of Tet2 function contributes to melanoma progression (Lian et al., 2012) . These results indicate that Tet2 plays an important role in tumorigenesis through its modulation of DNA demethylation and activation of yet unappreciated oncogenes. However, Tet2 lacks the N-terminal CxxC domain, a Zn 2+ -chelating domain that can bind with unmethylated CpG dinucleotides of the DNA sequence (Ko et al., 2013) . Previous studies have shown that VPRBP-mediated monoubiquitylation can enhance the ability of Tet2 to bind to DNA (Nakagawa et al., 2015) , whereas WT1 can recruit Tet2 to regulate expression of WT1 target genes and suppress leukemia cell proliferation . Nevertheless, the precise mechanism by which Tet2 regulates activation of its target gene is still unclear.
Methyl-CpG-binding domain (MBD) family proteins are highly conserved in all vertebrates and are capable of selectively recognizing and binding to methylated CpG dinucleotides through their methylCpG binding domain (Hendrich and Bird, 1998) . However, an exception to this general rule is the case of MBD3, which cannot do so due to lack of the conserved motif (Clouaire and Stancheva, 2008) . In addition, there are two conserved homologous genes of MBD3, MBD3L1 and MBD3L2, that lack the MBD domain of MBD3 but share a 42% similarity with it (Clouaire and Stancheva, 2008) . The function of MBD family proteins are mainly dependent on the MBD domain, which causes the genome-wide localization of MBD proteins at methylated-CpG-dense and inactive regulatory regions (Baubec et al., 2013) . However, an MeCP2 variant, in which the MBD domain is deleted, is preferably located at open accessible chromatin regions (Baubec et al., 2013) , indicating that MBD family proteins lacking MBD domains might be activators of gene expression rather than repressors. It has been reported that MBD3 family proteins are associated with gene activation (Brown and Szyf, 2007) . Recent studies have shown that MBD3 can bind 5mC oxidation derivatives (Iurlaro et al., 2013; Yildirim et al., 2011) , which are the intermediates in the demethylation process, inspiring us to further explore whether MBD3 and its homologs function in the process of DNA demethylation mediated by Tet proteins.
In the present study, we found that both MBD3 and MBD3L2 enhance the enzymatic activity of Tet2. In addition, MBD3L2 enhances Tet2-mediated DNA demethylation, most likely by reinforcing the accessibility of substrates to the C-terminal cysteine-rich dioxygenase domain of Tet2, leading to the activation of a group of oncogene expression. Our findings provide a new model of Tet regulation, indicating a potential role of the MBD3-Tet2 axis in the epigenetic control of tumorigenesis.
RESULTS

MBD3 and MBD3L2 co-occupy chromatin with Tet2
In order to explore whether MBD3 family proteins function in the process of DNA demethylation mediated by Tet proteins, we performed immunofluorescence experiments to show the localization of MBD3 and Tet2 in mammalian cells. We transiently transfected HEK293T cells with HA-Tet2 and Myc-MBD3, and the confocal microscopic analysis of the immunofluorescence staining revealed that both the exogenously expressed Tet2 and MBD3 localized in the nucleus (Fig. 1A) .
MBD3L2 is homologous to MBD3, but does not contain an MBD domain, which is specifically expressed in germ cells and related tumors (Iurlaro et al., 2013; Yildirim et al., 2011) . As MBD3L2 is only expressed at a low level in somatic cells (Jin et al., 2008) , including in HEK293T cells, we constructed a plasmid that expressed a tagged MBD3L2 and transfected it into HEK293T cells to explore the localization of MBD3L2. After 48 h of Myc-MBD3L2 and HA-Tet2 transient transfection, immunofluorescence imaging of the construct tags showed that MBD3L2 localized in the nucleus and, more interestingly, it appeared that MBD3L2 colocalized with Tet2 in the nucleus (Fig. 1A) .
To further define whether MBD3 and MBD3L2 colocalize with Tet2, we investigated the genome-wide distribution of MBD3 and Tet2 in mammalian cells by chromatin-immunoprecipitationsequencing (ChIP-seq). Given that Tet2 only weakly associates with chromatin, it is challenging to successfully perform ChIP (Deplus et al., 2013) . Hence, Tet2-overexpressing cells were sequentially cross-linked with disuccinimidyl glutarate (DSG) and formaldehyde, and then we performed Tet2 ChIP . ChIP followed by real-time quantitative PCR (ChIP-qPCR) proved that this technique is suitable for Tet2 ChIP (Fig. S1A ). Bioinformatics analysis of ChIP-seq data revealed that there were 34,821 Tet2-specific binding peaks genome wide, which were enriched at promoter regions (Fig. 1B) . Analysis of Tet2-binding peaks at each class of genomic elements indicated that Tet2 was more enriched at promoters [observed/random (obs/ rand)=4.1] and exons (obs/rand=5.5) relative to introns and intergenic regions (Fig. 1C) . Recently, Shimbo et al. have successfully conducted MBD3 ChIP in human MCF7 cells using DSG and formaldehyde for crosslinking ( Fig. S1B) (Shimbo et al., 2013) . Although Tet2 and MBD3 ChIP-seq data are from different cell types, we surprisingly found that 7504 MBD3 ChIP peaks (P-value <10
−16 , hypergeometric test) overlapped with the Tet2-binding peaks. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis showed that the overlapping genes are enriched in those annotated as 'cancer pathway' (Fig. S1C) , which implies that the regulation of Tet2 activity might be associated with cancer development.
In addition, we completed an MBD3L2 ChIP-seq in the HEK293T cells after the transfection of tagged MBD3L2, and found that MBD3L2 was more enriched at promoters (obs/ rand=5.8) and exons (obs/rand=7.3) relative to introns and intergenic regions (Fig. 1C) . Further analysis indicates that more than half of the MBD3L2-binding peaks overlapped with the Tet2 peaks ( Fig. 1D ) and the overlapping genes were also enriched in those annotated as cancer pathway (Fig. S1D) . Furthermore, the MBD3L2 binding profile is similar to the genomic distribution observed for Tet2 in HEK293T cell lines (Fig. 1E,F) . We further conducted ChIP-qPCR analysis and found that Tet2 and MBD3 or MBD3L2 were enriched at Tet2 target sites in HEK293T cells (Fig. S1E-G) , further validating the colocalization of Tet2 and MBD3 family proteins. These results indicate that MBD3L2 colocalizes with Tet2 in nucleus, which inspired us to further investigate the biological effects of MBD3 and MBD3L2 on Tet2 in mammalian cells.
MBD3 and MBD3L2 enhance Tet2 enzymatic activity by mediating 5hmC generation MBD3L2 expression occurs in oocyte and germ cell tumors, whereas MBD3L1 is specifically expressed in haploid male germ cells (Jin et al., 2008) . It has been reported that MBD3L1 and MBD3L2 do not possess a direct DNA demethylation function (Jin et al., 2008) , but because we found that MBD3 and MBD3L2 cooccupy the same sites as Tet2 in mammalian cells, it was still intriguing to explore whether they had regulatory effects on Tet2 enzymatic activity. Therefore, HEK293T cells were transiently transfected with MBD3, MBD3L1, MBD3L2 or Tet2. We used anti-HA antibody to purify Tet2 and MDB3 family proteins and eluted fully functional Tet2 and MBD3 family proteins with HA peptide (Fig. S2A) . We use high-salt solution to wash the proteins during the purification to remove the genomic DNA contamination as much as possible. We used the parallel reactions without adding methylated oligonucleotide to perform a liquid-chromatography tandem mass spectrometry (LC-MS/MS) assay, and the results show that 5hmC was not detected and deoxycytosine (dC), 5mC and deoxyguanosine (dG) were detected less frequently. Moreover, the dG content was only a hundredth of our methylated oligonucleotide sample, which will not affect the conclusion (Fig. S2B) . The 120-bp DNA fragment containing completely methylated cytosine was artificially made by PCR, owing to the substrate of cytosine replaced by 5mC during PCR amplification. The purified Tet2 and MBD3 family proteins were incubated with methylated DNA fragments at 37°C for 1 h. The DNA was extracted, digested and analyzed by LC-MS/MS, and the enzymatic activity of Tet2 was measured by 5hmC generation. A standard 5hmC nucleoside was used to verify the effectiveness of the LC-MS/MS method. N-oxalylglycine [NOG, a 2-oxoglutarate (2-OG) analog] was used to replace part of the 2-OG for the reaction and the results show that NOG can repress half of Tet2 enzymatic activity ( Fig. 2A) . Interestingly, addition of MBD3 increased the 5hmC level by about fourfold. However, MBD3L1 had no effects on modulating Tet2 activity ( Fig. 2A) . Surprisingly, MBD3L2 together with Tet2 could increase the 5hmC production by 13-fold compared to Tet2, suggesting that MBD3L2 has a stronger effect on regulating Tet2 enzymatic activity ( Fig. 2A; Fig. S2C ). Moreover, incubation of MBD3L2 with Tet1 or Tet3 did not result in increased Tet2 activity (Fig. S3A) , indicating that MBD3L2 functions specifically with Tet2. In order to investigate whether recombinant MBD3L2 protein enhances the activity of Tet2 protein, recombinant proteins purified from Escherichia coli were used in the enzymatic analysis. Our data show that recombinant MBD3L2 can also increase the enzymatic activity of recombinant Tet2 in vitro (Fig. S3B ). In addition, DNA fragments treated with the CpG-specific bacterial methyltransferase M.SssI was used as the substrate of the enzymatic activity, to make sure that the enhancement also has an effect in the context of CpG dinucleotides (Fig. S3C ). We found that purified full-length Tet2 protein degraded readily in vitro, which has been reported previously (Hu et al., 2013) . The Tet2 protein we used is purified from HEK293T cell and the amount of Tet2 protein is limited. In addition, the newly published data (Guo et al., 2015) indicate that Tet proteins are evolutionarily tuned to be less reactive towards 5hmC, therefore the generation of 5fC and 5caC is far less than 5hmC. When we increase the amount of Tet2 protein in enzymatic activity, we found that 5fC and 5caC can be detected, moreover, the amount of 5fC and 5caC increased with the addition of MBD3L2 in vitro.
Given that MBD3L2 can enhance the enzymatic activity of Tet2 greatly, we attempted to detect a physical interaction between MBD3L2 and Tet2 in mammalian cells. We transfected SBP-MBD3L2 and Flag-Tet2 into HEK293T cells, and performed coimmunoprecipitation with antibodies specific to the different tags. MBD3L2 could specifically pull down the Tet2 protein and vice versa (Fig. 2B ,C), indicating that MBD3L2 can physically interact with Tet2 in mammalian cells. Empty vectors were used in the coimmunoprecipitation experiment to prove the specificity of Tet2 and MBD3L2, and β-actin was included as the negative control. It has been acknowledged that the C-terminal cysteine-rich dioxygenase domain is responsible for the enzymatic activity of Tet2 (Hu et al., 2013) . To confirm which part of Tet2 protein interacts with MBD3L2, we transfected the Tet2 cysteine-rich dioxygenase domain or the region of Tet2 lacking this domain (denoted cysteine-rich dioxygenase minus, see schematic in Fig. 2D ) together with MBD3L2 into HEK293T cells. MBD3L2 can clearly pull down the Tet2 cysteine-rich dioxygenase domain but failed to pull down the cysteine-rich dioxygenase minus part of Tet2 (Fig. 2D ), which demonstrates that MBD3L2 might enhance the enzymatic activity of Tet2 by directly interacting with the cysteinerich dioxygenase domain.
To test this, we purified Tet2 cysteine-rich dioxygenase proteins with a HA tag from HEK293T cells, then incubated them with MBD3L2 proteins and methylated DNA fragments. We measured 5hmC level by LC-MS/MS. MBD3L2 together with the Tet2 cysteine-rich dioxygenase domain increased the 5hmC level by about twofold (Fig. 2E) . Moreover, when we measured the 5fC and 5caC levels by LC-MS/MS, it was very clear that 5fC and 5caC levels increased accordingly when MBD3L2 was co-transfected with the Tet2 cysteine-rich dioxygenase domain ( Fig. 2E; Fig. S2D ). The above results suggest that MBD3L2 promotes not only the first step of 5mC oxidation, but also the subsequent oxidation mediated by the Tet2 cysteine-rich dioxygenase.
MBD3L2 enhances the Tet2 DNA-binding affinity As Tet2 lacks the DNA-binding domain, we speculated that the interaction of MBD3L2 with Tet2 might either guide Tet2 to the targeted methylated DNA sequences or modify the affinity of the Tet2 protein to its substrate. Hence, we performed electrophoretic mobility shift assay (EMSA) experiments and found that Tet2 and its cysteine-rich dioxygenase domain can bind with the substrate, methylated or unmethylated DNA (Fig. 3) . Moreover, an EMSA experiment of Tet2 and its cysteine-rich dioxygenase domain shows that MBD3L2 increases Tet2 binding to the methylated DNA, and this binding affinity is clearly increased in a dose-dependent manner (Fig. 3A) . However, MBD3L2 cannot bind with the substrate (Fig. 3B ) (Jin et al., 2005) . Moreover, the binding affinity between the Tet2 cysteine-rich dioxygenase domain and unmethylated DNA cannot be enhanced by MBD3L2 (Fig. 3C ), indicating that MBD3L2 has a specific enhancement on the ability of Tet2 to bind methylated DNA. Collectively, these results support that MBD3L2 mainly interacts with the Tet2 cysteine-rich dioxygenase domain to increase its binding affinity to the methylated DNA for regulating Tet2-mediated oxidation.
In order to investigate whether MBD3L2 increases the affinity of Tet2 DNA binding in vivo, we performed a ChIP-qPCR analysis. This indicated that co-transfected MBD3L2 increased Tet2 enrichment at target regions. In addition, we transfected MBD3L2 small interfering RNA (siRNA) to knock down the overexpressed MBD3L2 and found that the enrichment of Tet2 binding at the target regions decreased accordingly (Fig. S1H ), indicating that MBD3L2 specifically increases the binding of Tet2 to target genes in HEK293T cells.
MBD3L2 promotes the demethylation process catalyzed by Tet2
In order to explore whether MBD3L2 enhances global DNA demethylation mediated by Tet2 in mammalian cells, we transfected Flag-MBD3L2 plasmids with or without HA-Tet2 into HEK293T cells. The genomic DNA was extracted, digested and detected with high-pressure liquid chromatography (HPLC) to measure 5mC and 5hmC levels for evaluating the enzymatic activity of Tet2 protein.
As expected, we discovered that MBD3L2 together with Tet2 significantly decreased global 5mC level compared with that when Tet2 was transfected alone ( Fig. 4A; Fig. S3D) , and the expression level of Tet2 protein made no difference between these two groups (Fig. 4A) . Accordingly, 5hmC was significantly increased in the MBD3L2 plus Tet2 group ( Fig. 4B; Fig. S3E) . These preliminary results demonstrate that MBD3L2 can promote Tet2 enzymatic activity by converting more 5mC into 5hmC in mammalian cells.
In order to verify the in vivo enhancement of MBD3L2 on genome-wide demethylation by Tet2, we transfected MBD3L2 and Tet2 plasmids into HEK293T cells, and then performed reduced representation bisulfite sequencing (RRBS) to measure DNA methylation status among different groups (Gu et al., 2011) . We found that MBD3L2 together with Tet2 could decrease the general DNA methylation level comparing with other groups (Table S1) . We compared the CpG density of affected regions and the results show that the CpG density of common RRBS regions tend to be higher than the CpGs in the human genome (P-value <2.2×10 −16 , Wilcoxon rank sum test), which is attributed to the enrichment of CCGG site by the method of RRBS (Fig. 4C) . Moreover, the demethylated regions induced by Tet2 and MBD3L2 was more likely to occur in relatively low CpG density regions (P-value <2.2×10 −16 , Wilcoxon rank sum test) (Fig. 4C) , which is consistent with the report that 5hmCG is enriched in low CpG regions (Yu et al., 2012) . Moreover, in order to examine whether MBD3L2 together with Tet2 can influence DNA methylation, we analyzed the RRBS data for the methylation status across the overlapping binding regions compared with the non-overlapping binding regions. As expected, the general DNA methylation level of the regions with overlapping binding by Tet2 and MBD3L2 decreased significantly (P-value=8.210051×10
−51 , Wilcoxon rank sum testing) compared with the non-overlapping counterpart (Fig. 4D) , which further confirms that MBD3L2 can function as a modulator of Tet2 and further affect the Tet2 target gene expression during tumor development.
As we could not distinguish 5mC and 5hmC with RRBS, we performed comparative hMeDIP-seq to detect the global 5hmC level to evaluate the efficiency of demethylation under different conditions (Fig. S4A) . The four samples were sonicated and ligated with adaptors containing a specific barcode sequence each (Tan et al., 2013) . hMeDIP and sequencing in an equal amount of four samples mixing in one reaction system was undertaken, as this can reduce the experimental error and variation among these four samples. The sequencing data were then separated by the different barcode sequences, and the difference in the 5hmC level of each sample leads to the different amounts of sequencing reads, which makes it possible to compare the 5hmC level between different samples with the sequencing data (Tan et al., 2013) . After normalizing to the correspondent input, the percentage of sequencing data for each sample represents the percentage 5hmC level for each sample in general (Tan et al., 2013) . The percentage of the sequencing reads in MBD3L2 together with Tet2 group was about 48.9%, an almost twofold increase compared with Tet2 and threefold relative to the control (Fig. 4E) . However, MBD3L2 alone had no effect on the 5hmC level (Fig. 4E) . Further analysis reflects that the increased 5hmC regions induced by MBD3L2 are enriched at transcription start sites (TSSs) and exon regions (Fig. S4B) . Moreover, we observed a significantly increased 5hmC level within the averaged gene bodies and TSS±5 kb regions in the MBD3L2 plus Tet2 group compared with other groups (Fig. 4F,G) . These results clearly demonstrate that MBD3L2 increases Tet2 demethylation activity but cannot influence DNA methylation by itself.
In order to investigate whether MBD3L2 and MBD3 affect endogenous Tet2, we transfected MBD3L2 and MBD3 in human acute lymphoblastic leukemia Jurkat cells, and we found that both MBD3L2 and MBD3 increases the global 5hmC level by about two times in Jurkat cells (Fig. 4H) , indicating that MBD3L2 and MBD3 enhance the enzymatic activity of endogenous Tet2.
MBD3L2 promotes Tet2 target gene expression by enhancing demethylation
In order to investigate the biological function of MBD3L2 regulating Tet2 enzymatic activity in mammalian cells, we extracted RNA and performed microarray profiling analysis, which shows that MBD3L2 together with Tet2 upregulated 1212 genes and downregulated 421 genes (deposited in the Gene Expression Omnibus database under accession GSE74915). Gene Ontology analysis showed that the upregulated genes were enriched in the category designated 'metabolic process' (Fig. 5A) , such as XRCC6 and LDHB, which are also target genes of Tet2 and MBD3L2. Moreover, the genes upregulated after MBD3L2 and Tet2 co-transfection not only take part in cellular metabolic process but might also be related to cancer development, such as IRF4 and HOXD1, which have been reported to be abnormally expressed in leukemia and breast cancer (Faryna et al., 2012; So et al., 2014 ). An qPCR experiment validated that MBD3L2 and Tet2 further increased the cancer-related genes expression compared to Tet2 itself (Fig. 5B) . We transfected HA-Tet2 and Tet2 siRNA sequentially in HEK293T cells, and the upregulated gene expression was reduced (Fig. S4C ). In addition, we found that a catalytically inactive mutant of Tet2 did not increase the expression of Tet2 target genes (Fig. S4D) . Furthermore, MBD3L2 co-transfected with mutant Tet2 did not enhance expression of these genes, indicating that the increased expression of Tet2 target genes mediated by MBD3L2 was dependent on the catalytic activity of Tet2.
Given that the 5hmC level of promoter and gene body regions were involved in upregulated gene expression (Song et al., 2011; Ficz et al., 2011) , we considered whether the upregulated gene expression mediated by MBD3L2 and Tet2 was dependent on the demethylation process. Accordingly, we analyzed the hMeDIP data on the promoter regions of those selected target genes and found that the 5hmC level of the target genes promoter was increased significantly by the MBD3L2-mediated effect on Tet2 protein (Fig. 5C ). To further quantify the 5hmC status at the specific locus within Tet2-target gene promoters, we performed glucosylated hydroxymethyl-sensitive qPCR (GluMS-qPCR), which enables a single-base-level quantification of the methylation status of CCGG sites. Our data show that co-transfection of MBD3L2 and Tet2 in HEK293T cells led to a significant increase of 5hmC at particular loci of the promoters or gene body regions in Tet2 target genes (Fig. S4E) . In summary, our results demonstrate that MBD3L2 reinforces the DNA demethylation process at Tet2 target regions, and induces the upregulation of target gene expression that might be involved in tumorigenesis.
DISCUSSION
Tet dioxygenases are able to catalyze the oxidation of 5mC into 5hmC and further oxidize 5hmC into 5fC and 5caC, which has revealed new pathways in the cytosine demethylation process. The Tet2-inactivating mutations in hematological malignancies and other solid tumors suggest that cellular transformation is in part caused by the dysregulation of 5mC conversion (Nakajima and Kunimoto, 2014) . It has been suggested that downregulation of Tet2 is responsible for the loss of 5hmC in melanoma cells and overexpression of Tet2 suppresses melanoma growth, indicating that 5hmC regulated by Tet2 affects melanoma progression (Lian et al., 2012) . Tet2 lacks the CxxC domain, through which Tet1 and Tet3 have been proven to bind methylated cytosine and non-CpG sequences , facilitating the recruitment of Tet proteins to their genomic targets. Thus, it was likely that other factors would be involved in the demethylation process on Tet2 target regions. Here, we show that MBD3 and its homolog MBD3L2 colocalize with Tet2 in the nucleus and exhibit the ability to increase the enzymatic activity of Tet2. As MBD3 is preferentially associated with CpG-rich promoters and enhancers marked by H3K4me3 or H3K27ac (Shimbo et al., 2013) , our results provide evidence that the MBD3 family might interact with Tet2 in fine-tuning the regulatory elements for gene expression. A report by Jin et al. (Jin et al., 2008) indicates that MBD3L2 has no direct effect on demethylation and the MBD3L2-knockout mouse is viable. In our experiments, we also find that MBD3L2 and MBD3 did not have a direct effect on demethylation; however, they could promote the demethylation mediated by Tet2. We propose that the complementary effects of MBD3 can function when MBD3L2 is knocked out. MBD3 is the only member of the MBD-protein family that lacks specificity towards methyl-CpGs in vitro due to evolutionary mutations in the MBD domain (Baubec et al., 2013) . It has been reported that the 60 N-terminal amino acids of MBD3 are important for MBD3 to be able to facilitate reprogramming in a Nanog-dependent manner (dos Santos et al., 2014) . Recent studies have shown that MBD3 can bind 5hmC and regulate gene expression. Surprisingly, here, we found that MBD3L2 was able to increase Tet2 enzymatic activity greatly, indicating that the C-terminal of MBD3 also plays a contributory role in the functioning of MBD3. In turn, another homolog of MBD3, MBD3L1, had no effects on Tet2 catalytic activity, revealing it is a particular regulation between MBD3L2 and MBD3. Additionally, it has been reported that both MBD2 and MBD3 possess the ability to induce DNA demethylation Wang et al., 2013) , nevertheless, few of these studies provide solid evidence or clarified the detailed mechanism. We found that MBD3L2 acts as a partner of Tet2 and that the interaction was mediated by the cysteine-rich dioxygenase domain of Tet2. Our EMSA experiments provided evidence that MBD3L2 increases the binding affinity of Tet2 and its cysteine-rich dioxygenase domain to their substrates, methylated DNA. We propose that the binding affinity enhancement modulates Tet2 activity because binding to methylated DNA is a prerequisite for the function of Tet2 in catalyzing 5mC hydroxylation. We propose that, on the initiation of the enzyme reaction, the increased binding affinity of Tet2 and methylated DNA might mean more 5mC is hydroxylated to generate 5hmC. However, at the end of the reaction, the increased binding affinity of Tet2 and methylated DNA traps the protein, and limits the reaction of Tet2 and its other substrate. Therefore, the increased binding affinity might regulate Tet2 activity dynamically. Kinetic analysis indicates that the Tet2 enzymatic efficiency can be defined as k cat /K m . Although an increased binding affinity would lead to an increased K m , in this case Tet2 would catalyze more 5mC and generate more 5hmC per second, which would lead to an increased k cat . In our experiment, the content of 5mC was excessive and the increased binding affinity made the enzymatic reaction rate increase, leading to an increase in k cat /K m , suggestive of an enhancement in the enzymatic efficiency of Tet2. There is some evidence that Tet2 activity can be enhanced by other factors. For example, it has been reported that PRDM14 induces DNA demethylation at that germlinespecific genes Piwil2 and Slc25a3, meanwhile, PRDM14 can also enhance the binding of Tet2 at or near the TSS of these genes (Okashita et al., 2014) . Recent studies have shown that histone H3 peptide induces the activation of de novo DNA methyltransferase by removal of Dnmt3a-mediated autoinhibition, which stimulates a configuration change Wang et al., 2013) . Considering that MBD3L2 enhances Tet2 binding affinity rather than binding with methylated DNA itself, whether the configuration of Tet2 is altered by MBD3L2 needs further investigation.
Traditionally, MBD3 has been shown to be involved in transcriptional repression; however, MBD3 is also required for embryonic development and pluripotent cell differentiation, and acts as a positive facilitator in the transcription-factor-mediated reprogramming of neural stem cells (NSCs) (dos Santos et al., 2014; Kaji et al., 2007) . Transcriptome analysis has shown that 61% of differentially expressed genes are downregulated after MBD3 deletion in ESCs, suggesting it to be a mediator of transcription-factor-induced gene activation. In somatic cells, MBD3 is essential for rRNA promoter demethyaltion and its absence results in the hypermethyaltion of rRNA gene promoter (dos Santos et al., 2014; Kaji et al., 2007) . Knowing this, it seems likely that MBD3 might be a mediator of transcriptionfactor-induced gene activation. Despite knowing that MBD3L2 is one homolog of MBD3, sharing 40% similarity with MBD3, the function of MBD3L2 remained unclear. Here, we show that both MBD3L2 together with Tet2 can upregulate a group of genes that are associated with metabolic process, suggesting that MBD3L2 and Tet2 might serve as general activators. Further experiments showed that the upregulation of Tet2-dependent genes was enhanced by MBD3L2, possibly due to effects on the demethylation process at Tet2 target regions. More importantly, most of the upregulated genes are associated with cancer. Given that MBD3L2 is specifically expressed in germ cell tumors, it needs further research to explore whether MBD3L2 has an effect on Tet2 in regulating germ cell tumorigenesis.
Our study provides evidence that MBD3 and its homolog MBDL2 promote Tet2 enzymatic activity, and that MBD3L2 enhances the demethylation process mediated by the Tet2 cysteine-rich dioxygenase domain, especially at overlapping binding regions between Tet2 and MBD3L2. We found that the binding affinity of Tet2 and methylated DNA was increased by MBD3L2, which contributes to Tet2 enzymatic activity enhancement. Moreover, MBD3L2 increases the expression of Tet2 target genes, such as HOXD1 and IRF4, which are closely linked with cancer development. Cumulatively, our results demonstrate that MBD3L2 can enhance Tet2-dependent gene expression, providing another regulatory pathway for Tet2 target genes and tumorigenesis.
MATERIALS AND METHODS
Antibodies
Antibodies against HA (Cell Signaling, C29F4; 1:3000 dilution), Flag (Abmart, M2008; 1:3000 dilution), Myc (Abcam, ab9106; 1:3000 dilution), rabbit IgG (Santa Cruz, sc-2027; 1:1000 dilution), SBP (Santa Cruz Biotechnology, SBC9-14; 1:3000 dilution) were purchased commercially. Endogenous Tet2 antibody was obtained from Dan Ye (Fudan University, Shanghai, China) and used at 1:1000 dilution.
Plasmids
The cDNA encoding full-length human MBD3L2 and MBD3 were cloned into HA, Myc-or GFP-tagged vectors ( pCMV-HA; pCMV-Myc; pCDH-GFP; pcDNA3.1 with SBP tag). DNA fragments of the Tet2 catalytic domain and catalytic minus domain (1-1098) were sub-cloned into the pCMV-HA vector.
Mouse Tet2-pCAG vector was obtained from Guoliang Xu (Chinese Academy of Sciences, Shanghai, China). The catalytically inactive mutant (CM) vector of Tet2 was obtained from Dan Ye.
Cell culture and transfection
Human embryonic kidney 293T (HEK293T) cells were cultured in Dulbecco's modified Eagle's medium (DMEM, HyClone) supplemented with 10% fetal calf serum (HyClone) at 37°C in 5% CO 2 . Human acute lymphoblastic leukemia Jurkat cells (Jurkat cells) were cultured in RPMI-1640 medium (HyClone) supplemented with 10% fetal calf serum (HyClone) at 37°C in 5% CO 2 . Plasmid transfection was carried out either by the calcium phosphate method (Spandidos and Wilkie, 1984) or by use of Lipofectamine 2000 (Invitrogen), and the cells were harvested 48 h after transfection.
Genomic DNA extraction
Genomic DNA was extracted with QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions. RNaseA/T1 was used in the process of DNA extraction to remove the RNA contamination in genomic DNA. The concentration and quality of genomic DNA were measured by NANODROP2000c (Thermo) and electrophoresis.
Co-immunoprecipitation
Cells were lysed in ice-cold lysis buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 0.15 M NaCl and 0.15% NP-40) containing protease inhibitor cocktail (Roche). Immunoprecipitation was carried out either by incubating Flag beads (Sigma), HA beads (Sigma), Dynabeads ® M-280 Streptavidin (Invitrogen) or rabbit IgG beads (Sigma) at 4°C with lysate for 6 h. Then the beads were washed four times with ice-cold lysis buffer.
Protein extraction for enzymatic analysis
Cells were lysed in ice-cold lysis buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 0.5 M NaCl and 0.15% NP-40) containing protease inhibitor cocktail (Roche). Immunoprecipitation was carried out either by incubating Flag beads (Sigma) or HA beads (Sigma) at 4°C with lysate for 6 h. Then the beads were washed four times with ice-cold lysis buffer. The proteins were eluted with Flag peptide (Sigma) or HA peptide (Sigma) at 4°C for 2 h.
In vitro Tet2 enzyme assays
Tet2 proteins were extracted from HEK293T cells with anti-Flag M2 Magnetic Beads, and the proteins were eluted with anti-Flag peptide. The 120-bp methylation DNA fragment (500 ng) was incubated with Tet2 (200 ng) or the Tet2 cysteine-rich dioxygenase protein domain (1 μg) in buffer containing 50 mM HEPES (pH 8.0), 100 mM NaCl, 2 mM ascorbate, 1 mM 2-oxoglutarate, 100 mM Fe(NH 4 ) 2 (SO 4 ) 2 , 1 mM DTT and 1 mM ATP at 37°C for 1 h (He et al., 2011) . The DNA was purified with a PCR purification kit (Qiagen) and the product DNA was denatured at 100°C for 10 min and further digested to nucleosides with 0.5 U nuclease P1 (Sigma-Aldrich) at 37°C for 16 h and 0.5 U CIP (NEB) at 37°C for 1.5 h. The 120-bp methylation DNA substrate contains 31 methylcytosine nucleotides (one methyl-CpG dinucleotide). The recombinant Tet2 and MBD3L2 proteins were obtained from Yanhui Xu (Fudan University, Shanghai, China).
M.SssI treatment
A 163-bp PCR-amplicon was methylated in vitro with bacterial CpG methyltransferase M.SssI (NEB, #M0226S). 1 μg DNA was treated with 1 μl (4 U/μl) M.SssI in buffer with SAM and incubated for 4 hours at 37°C. Then the DNA was purified with a PCR purification kit (Qiagen).
LC-MS/MS analysis
The digested samples were subjected to LC-MS/MS using a Shimadzu LC (LC-20AB pump) system coupled with TSQ-vantage triple quadrupole mass spectrometer (Thermo). A C18 column (250 mm×2.1 mm I.D., 5-μm particle size, ULTIMATE) was used. The mass spectrometer was optimized and set up in selected reaction monitoring (SRM) scan mode for monitoring the [M+H+] of dC (m/z 228.2→112.2), 5mC (m/z 242.1→126.1), 5hmC (m/z 258.1→142.1), 5fC (m/z 256.1→140.1), 5caC (m/z 272.1→156.1) and dG (m/z 268.1→152.3). Standard curves for 5hmC, 5fC, 5caC, and dG were constructed using a weighted (1/X) linear regression of the integrated areas of the analyte (Y) against the corresponding six concentrations of the analyte (X, ng/ml). The Xcalibur 2.2 sp1 was used for integrated areas analysis. The concentration of samples was calculated by interpolation from the standard curves. The standard nucleosides of dC, 5mC and dG were bought from Thermo; 5hmC was bought from Zymo Research. The standard nucleosides of 5fC and 5caC were obtained from Yanhui Xu.
HPLC analysis
Reaction products from the LC-MS/MS were analyzed on a ShimazuLC (LC-20AD pump) machine with an AQ-C18 column of 5-μm particle size, 25 cm×4.6 mm. The mobile phase was 10 mM KH2PO4, pH 3.7, running at 1 ml per min, and the detector was set at 280 nm.
EMSA
The biotin-conjugated 16-bp DNA [upper strand: 5′-TA(Cm) CGTACAGTACACTA-3′] (10 pmol) was incubated with Tet2 (100 ng) or the Tet2 cysteine-rich dioxygenase domain (500 ng) purified in a total volume of 20 µl of reaction mixture. An increasing amount of MBD3L2 (100 ng, 300 ng and 600 ng) was used in the different groups. The experiment was performed according to the instructions of LightShift Chemiluminescent EMSA kit (Thermo). The membrane was placed in a film cassette and exposed to X-ray film.
ChIP
Cells were first fixed with 2 mM disuccinimidyl glutarate (DSG) (Thermo) for 45 min at room temperature, washed twice with PBS and then doublefixed with 1% formaldehyde for another 10 min at room temperature . The reaction was stopped with 0.125 M glycine solution for 5 min. Nuclei were extracted with cell lysis buffer (10 mM HEPES pH 7.9, 0.5% NP40, 1.5 mM MgCl 2 , 10 mM KCl and 1× protease inhibitor cocktail) and dissolved in nuclear lysis buffer (50 mM Tris-HCl pH 8.1, 10 mM EDTA, 0.3% SDS and 1× protease inhibitor cocktail). After sonication, the soluble chromatin was incubated with anti-HA antibody (Cell Signaling; C29F4) overnight followed by incubation with Protein A magnetic beads (Millipore). The immunoprecipitated DNA was purified with the PCR Purification Kit (Qiagen).
ChIP-seq analysis
Public MBD3 ChIP-seq data used for analyses was MCF-7_MBD3 (accession number GSM1089817) and MCF-7_MBD3_input (accession number GSM1089816). Sequenced reads of Tet2 ChIP-seq, MBD3L2 ChIP-seq and input libraries were combined for replicate samples and filtered based on a mean base quality score <20. Filtered reads were then aligned to the human reference genome [University of California, Santa Cruz (UCSC) assembly hg19, GRCh37] using the Bowtie short-read alignment program (v0.12.7) to retain reads mapped to unique genomic locations with at most two mismatches. Unique and monoclonal reads were used in subsequent peak-calling analyses. Given that the average DNA fragment length used in ChIP-seq was 400 bp, each sequence was extended to 400 bp. A summary of ChIP-seq data is shown in Table S2 . The peaks were identified using the MACS software (version 1.4) with the P <1×10 −5 and a false discovery rate (FDR) of <0.01; the IgG sample was used as a control for ChIP samples (Zhang et al., 2008) .
Heatmaps
Heatmaps were generated by plotting for all the annotated RefSeq genes' enrichment as a color gradient at their relative location using the annotated gene TSS as the reference. Genes were first ordered using the average tag density significance in the 1-kb region around the TSS for Tet2 ChIP-seq in HEK293T cells.
Overlapping binding regions of MBD3L2 and Tet2
The overlapping binding regions of Tet2 and MBD3L2 are defined as the Tet2 peaks whose overlapping ratios of MBD3L2 peaks are above 50%. The overlapping binding genes are defined as the genes whose promoter (1000-bp upstream and downstream of the TSS) located at the overlapping binding regions of Tet2 and MBD3L2. The overlapping ratios were identified using bedtools IntersectBed (Quinlan and Hall, 2010) .
CpG density
The CpG count is the number of CG dinucleotides in the genome. The CpG percentage (i.e. the CpG density) of a region is the ratio of CpG nucleotide bases (twice the CpG count) to the length of the window centered on this region. The length of the window is set as 200 bp. Genomic regions are composed of all the CG dinucleotides in the human reference genome (hg19). Demethylated regions include the CpG sites whose methylation level decreased in RRBS_Tet2 and further decreased in RRBS_Tet2 +MBD3L2. Common RRBS regions consist of the common sites of RRBS_Control, RRBS_Tet2 and RRBS_Tet2+MBD3L2.
Analysis of methylation change
Firstly, we analyzed the ChIP-seq data of Tet2 and MBD3L2. The overlapping binding regions of Tet2 and MBD3L2 are defined as the Tet2 peaks whose overlapping rates with MBD3L2 peaks are above 50%. The non-overlapping binding regions of Tet2 and MBD3L2 are the Tet2 peaks whose overlapping rates of MBD3L2 peaks are below 10%. Secondly, for each region defined above, we calculated the average methylation level of the two samples, Tet2 and Tet2+MBD3L2, respectively. Then we defined the methylation change between the two samples in a region as the ratio of average methylation level of Tet2 to that of Tet2+MBD3L2. We further compared the methylation change of the overlapping regions and non-overlapping regions by box plot and Wilcoxon rank sum testing.
GO analysis and KEGG pathway annotation
GO analysis and KEGG pathway enrichment analysis for regulated genes were performed by using the database for annotation, visualization and integrated discovery (DAVID) online tools (http://david.abcc.ncifcrf.gov/) (Huang et al., 2009 ).
Comparative hMeDIP-seq Library construction (adding adaptor-containing barcode sequence) Genomic DNA was sonicated to <500 bp with a Bioruptor sonicator (Diagenode) and quantified using the NANODROP2000c (Thermo) according to the manufacturer's manual. The quantified DNA (1 μg of each sample) were sonicated to less than 500 bp with a Bioruptor sonicator (Diagenode). The sonicated DNA fragments were end-repaired using the End-It DNA End Repair Kit (EPICENTRE Biotechnologies) according to the manufacturer's instructions, followed by treatment with Klenow fragment 3′-5′ exonuclease (NEB) and dATP to generate a protruding 3′ A for ligation with the adaptor containing a specific barcode sequence. The barcode sequences were (four-base index) TTAGGC, GATCAG, AGTTCC and GTCCGC within the adaptor. Then the four samples were mixed together.
hMeDIP Equal amounts (1 μg each sample) of barcode-tagged genomic DNA from four samples were pooled together in one tube (Tan et al., 2013) . The mixed DNA was denatured and diluted with immunoprecipitation buffer (10% was taken off as input at this step). The denatured DNA was incubated with 4 ml anti-5hmC antibody (active motif, 39791) at 4°C overnight. Antibody-DNA complexes were captured by protein A/G beads, and the enriched 5hmC-containing DNA fragments (hMeDIP product) were purified with a Qiagen Mini Gel Purification Kit.
Library amplification
The hMeDIP product, as well as input DNA, was amplified for 16 cycles, and the products ranging from 400 to 500 bp were purified by Qiagen Mini Gel Purification Kit.
Next-generation sequencing
The amplified libraries were submitted for cluster growth and sequencing with the Illumina Genome Analyzer II (GAII).
hMeDIP-seq data processing
We separated the raw sequence reads of hMeDIP and input into different files according to the specific barcode sequence of each sample. Sequence reads were mapped onto the reference human genome using the Bowtie (v0.12.7) algorithm. The peaks of hMeDIP-seq were identified using the MACS software (version 1.4) with the default parameters and a P-value cut-off of <10 −5 .
Peak calling
The peaks of hMeDIP-seq were identified using the MACS software (version 1.4) with the default parameters.
RRBS 500 ng of genomic DNA was digested with the methylation-insensitive restriction digest enzyme Msp1 (NEB), which cleaves DNA at CCGG sites creating fragments high in CpG content (Gu et al., 2011) . The DNA was purified using the QIAquick PCR Purification Kit (Qiagen). Samples were end-repaired and A-tailed using a Klenow fragment (New England Biolabs, Inc). TruSeq™ adaptors (Illumina, Inc., San Diego, CA) were ligated to the modified DNA ends using T4 DNA ligase (New England Biolabs, Inc.). We excised gel-separated samples ranging from 150-400 bp and purified them with the QIAquick Gel Extraction Kit (Qiagen). The sample was bisulfite modified and PCR amplified to enrich for fragments containing high CpG content. Samples were submitted for sequencing on the Illumina HiSeq™ instrument.
RRBS data analysis
In brief, RRBS sequencing raw reads were trimmed with trim_galore (v0.4.0) with default parameters to remove adaptor sequence and lowquality sequence, and then the rest reads were aligned to human reference genome (hg19, downloaded from http://genome.ucsc.edu) using BSMAP (v2.6) with default parameters (Xi and Li, 2009) ; finally a script, methratio. py was used for extracting methylation ratios from BSMAP mapping results NE.Ref (Gu et al., 2011) .
Microarray experiment
Total RNA was extracted and RNA quality was evaluated using NanoDrop ND-1000 and denaturing agarose gel electrophoresis. The Arraystar Human LncRNA Microarray (v2.0) was used to detect RNA expressions, the Agilent Feature Extraction software (v11.0.1.1) to analyze array images, and the GeneSpring GX software package (v 11.5.1, Agilent Technologies) to analyze intensity and normalization. Probes with three flags (Present or Marginal) in three samples were selected for downstream analysis. Differential expression mRNAs were identified by a cut-off of fold change ≥2. The data have been deposited in the Gene Expression Omnibus database under accession code GSE74915.
GluMS-qPCR analysis
The 5hmC level in Tet2-binding regions was measured by a restrictionenzyme-based assay (EpiMark kit, New England Biolabs). Genomic DNA was treated with or without T4 Phage b-glucosyltransferase, and then digested by MspI or no enzyme. The MspI-resistant fractions were quantified by qPCR and normalized to the mock digestion. PCR primers and siRNA sequence are listed in Table S3 .
Statistical analysis
Statistical analysis was performed with Student's t-test. All data shown represent the results obtained from triplicate independent experiments with mean±s.e.m. shown. Values of P<0.05 were considered statistically significant.
